A one-time, personalized cell therapy from Kyverna Therapeutics has demonstrated improved mobility and reduced disabilities in patients suffering from stiff person syndrome, a rare neurological autoimmune disorder, as revealed by recent study results. This advancement marks a significant milestone in the treatment landscape for this challenging condition.
Kyverna is preparing to submit this innovative therapy to the Food and Drug Administration by mid-year. Should the therapy receive approval, it would not only be the first treatment specifically for stiff person syndrome but also the inaugural personalized CAR-T therapy for any autoimmune disease to enter the market. This could set a precedent for future therapies targeting similar conditions.
While CAR-T therapies have traditionally been confined to the realm of blood cancers, the potential to utilize engineered T cells for immune system modulation in autoimmune diseases has prompted a strategic pivot among biotech firms. This shift underscores a growing interest in developing CAR-T applications beyond oncology, potentially transforming the treatment paradigm for autoimmune disorders.
Get started today with Solo access →
